OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
February 01, 2010
Shireâ€™s Second Act
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?
Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation.
R&D is surging, but new methods and data raise new manufacturing and regulatory challenges.
Sales compensation practices are due for an overhaul in 2010.
Innovation won't happen until the industry is ready to sit down and make a big change.